Pharmaceutical expenditures, the reference price system and competition in the pharmaceutical market. A register study

Näytä kaikki kuvailutiedot

Permalink

http://urn.fi/URN:NBN:fi-fe2018052524702

Tilaa julkaisu

Tilaa julkaisu
Julkaisun nimi: Pharmaceutical expenditures, the reference price system and competition in the pharmaceutical market. A register study
Tekijä: Koskinen, Hanna
Kuuluu julkaisusarjaan: Studies in social security and health 150
ISSN: 1238-5050 (ISSN-L)
1238-5050 (print)
2323-7724 (pdf)
ISBN: 978-952-284-039-4 (print)
978-952-284-040-0 (pdf)
Tiivistelmä: This study examines the impact of the implementation of a generic reference price system on pharmaceutical prices and competition within the market. The focus is particularly on antipsychotic medications. Furthermore, the impact of reference pricing on previously implemented generic substitution is assessed. Antipsychotics and antidepressants were, in terms of value, among the fastest growing pharmaceutical groups in Finland at the turn of the 21st century. For antipsychotics, most of the cost growth resulted from the rise in the mean daily cost of treatment, whereas the main reason for antidepressant cost growth was the increased number of patients. The implementation of reference pricing decreased the daily cost of the studied antipsychotics. The decreases ranged from 30% to 66% in the short term and from 25% to 51% in the medium-to-long term. When the study was extended to other pharmaceutical groups, the average decrease was 35% at the end of the first year, 56% at the end of the second year and 60% at the end of the third year. However, there were large differences in the size of the decrease between groups. Being included in the reference price system had the largest decreasing impact on prices. However, the reference price system’s impact on prices appeared to be waning; the later an active substance was included in the system, the higher the price level remained. In addition, the impact of the reference price system on previously implemented generic substitution remained low, and 2.5 years after the implementation of the reference price system it was almost non-existent. Generic pharmaceutical markets are highly concentrated in Finland. In addition, there is an overall lack of transparency in the pharmaceutical distribution chain. Further research is needed on the barriers of entry and on the role different operators of the pharmaceutical distribution chain have in promoting price competition in the generic market sector.
Kuvaus: 132 pp.
URI: http://hdl.handle.net/10138/235595
URN:NBN:fi-fe2018052524702
Päiväys: 2018
Avainsanat: reference prices
systems
generic substitution
prices
competition
drugs, generic
generic products
medicines
antipsychotic agents
market
costs
Tilaushinta: 28.00 euro


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Tutkimuksia150.pdf 831.4KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot